HK1201750A1 - 使用 激酶抑制劑的癌症治療 - Google Patents
使用 激酶抑制劑的癌症治療Info
- Publication number
- HK1201750A1 HK1201750A1 HK15102376.3A HK15102376A HK1201750A1 HK 1201750 A1 HK1201750 A1 HK 1201750A1 HK 15102376 A HK15102376 A HK 15102376A HK 1201750 A1 HK1201750 A1 HK 1201750A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tor
- cancer
- treatment
- kinase inhibitors
- tor kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261611361P | 2012-03-15 | 2012-03-15 | |
| US201261715323P | 2012-10-18 | 2012-10-18 | |
| PCT/US2013/031206 WO2013138557A1 (en) | 2012-03-15 | 2013-03-14 | Treatment of cancer with tor kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1201750A1 true HK1201750A1 (zh) | 2015-09-11 |
Family
ID=48014336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15102376.3A HK1201750A1 (zh) | 2012-03-15 | 2015-03-09 | 使用 激酶抑制劑的癌症治療 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20130245026A1 (zh) |
| EP (1) | EP2825170B1 (zh) |
| JP (3) | JP2015510891A (zh) |
| KR (3) | KR102122617B1 (zh) |
| CN (2) | CN104519885A (zh) |
| AU (1) | AU2013203153B2 (zh) |
| BR (1) | BR112014022703A2 (zh) |
| CA (1) | CA2866872A1 (zh) |
| EA (1) | EA028414B1 (zh) |
| ES (1) | ES2677874T3 (zh) |
| HK (1) | HK1201750A1 (zh) |
| IL (1) | IL234602B (zh) |
| MX (1) | MX360878B (zh) |
| MY (1) | MY174022A (zh) |
| NI (1) | NI201400111A (zh) |
| NZ (1) | NZ628416A (zh) |
| PH (1) | PH12014502029B1 (zh) |
| SG (1) | SG11201405707XA (zh) |
| TW (1) | TWI583385B (zh) |
| UA (1) | UA114315C2 (zh) |
| WO (1) | WO2013138557A1 (zh) |
| ZA (1) | ZA201406706B (zh) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130245026A1 (en) * | 2012-03-15 | 2013-09-19 | Signal Pharmaceuticals, Llc | Treatment of cancer with tor kinase inhibitors |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| AU2014207641A1 (en) | 2013-01-16 | 2015-08-06 | Signal Pharmaceuticals, Llc | Substituted Pyrrolopyrimidine Compounds, compositions thereof, and methods of treatment therewith |
| MX2015014455A (es) | 2013-04-17 | 2016-07-21 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer. |
| NZ631082A (en) * | 2013-04-17 | 2017-06-30 | Signal Pharm Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
| MX2015014590A (es) | 2013-04-17 | 2016-03-03 | Signal Pharm Llc | Tratamiento de cancer con dihidropirazino-pirazinas. |
| BR112015026238A8 (pt) | 2013-04-17 | 2019-12-24 | Signal Pharm Llc | composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit |
| BR112015026257B1 (pt) | 2013-04-17 | 2022-12-20 | Signal Pharmaceuticals, Llc | Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit |
| AU2014254050B2 (en) | 2013-04-17 | 2018-10-04 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| WO2014172424A1 (en) * | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| US9474757B2 (en) | 2013-04-17 | 2016-10-25 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
| CA2912627C (en) | 2013-05-29 | 2022-03-15 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| WO2015160880A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| ES2823756T3 (es) | 2014-04-16 | 2021-05-10 | Signal Pharm Llc | Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR |
| JP2017520603A (ja) | 2014-07-14 | 2017-07-27 | シグナル ファーマシューティカルズ，エルエルシー | 置換ピロロピリミジン化合物を使用するがんの治療方法及びその組成物 |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| KR20200019229A (ko) | 2017-06-22 | 2020-02-21 | 셀진 코포레이션 | B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009004019A (es) * | 2006-10-19 | 2009-06-19 | Signal Pharm Llc | Compuestos heteroarilo, composiciones de los mismos, y uso de los mismos como inhibidores de proteina cinasa. |
| RU2478635C2 (ru) * | 2006-10-19 | 2013-04-10 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Гетероарильные соединения, содержащие их композиции и способы лечения с применением этих соединений |
| WO2010022243A1 (en) * | 2008-08-20 | 2010-02-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemoprevention of head and neck squamous cell carcinomas |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| MX341704B (es) | 2009-10-26 | 2016-08-31 | Signal Pharm Llc | Métodos de síntesis y purificación de compuestos de heteroarilo. |
| US20120028972A1 (en) * | 2010-07-30 | 2012-02-02 | Lilly Wong | Biomarker assays for detecting or measuring inhibition of tor kinase activity |
| US20130245026A1 (en) * | 2012-03-15 | 2013-09-19 | Signal Pharmaceuticals, Llc | Treatment of cancer with tor kinase inhibitors |
-
2013
- 2013-03-14 US US13/803,061 patent/US20130245026A1/en not_active Abandoned
- 2013-03-14 KR KR1020147028707A patent/KR102122617B1/ko active IP Right Grant
- 2013-03-14 EP EP13713006.8A patent/EP2825170B1/en active Active
- 2013-03-14 CA CA2866872A patent/CA2866872A1/en not_active Abandoned
- 2013-03-14 UA UAA201411218A patent/UA114315C2/uk unknown
- 2013-03-14 TW TW102109160A patent/TWI583385B/zh active
- 2013-03-14 EA EA201491699A patent/EA028414B1/ru not_active IP Right Cessation
- 2013-03-14 CN CN201380024859.XA patent/CN104519885A/zh active Pending
- 2013-03-14 NZ NZ628416A patent/NZ628416A/en not_active IP Right Cessation
- 2013-03-14 JP JP2015500596A patent/JP2015510891A/ja active Pending
- 2013-03-14 AU AU2013203153A patent/AU2013203153B2/en not_active Ceased
- 2013-03-14 KR KR1020217017407A patent/KR20210071101A/ko not_active Application Discontinuation
- 2013-03-14 WO PCT/US2013/031206 patent/WO2013138557A1/en active Application Filing
- 2013-03-14 SG SG11201405707XA patent/SG11201405707XA/en unknown
- 2013-03-14 MX MX2014011077A patent/MX360878B/es active IP Right Grant
- 2013-03-14 ES ES13713006.8T patent/ES2677874T3/es active Active
- 2013-03-14 CN CN201811057528.7A patent/CN108992446A/zh active Pending
- 2013-03-14 MY MYPI2014702568A patent/MY174022A/en unknown
- 2013-03-14 KR KR1020207016306A patent/KR20200070416A/ko not_active IP Right Cessation
- 2013-03-14 BR BR112014022703-9A patent/BR112014022703A2/pt not_active IP Right Cessation
-
2014
- 2014-09-11 IL IL234602A patent/IL234602B/en active IP Right Grant
- 2014-09-12 PH PH12014502029A patent/PH12014502029B1/en unknown
- 2014-09-12 NI NI201400111A patent/NI201400111A/es unknown
- 2014-09-12 ZA ZA2014/06706A patent/ZA201406706B/en unknown
-
2015
- 2015-03-09 HK HK15102376.3A patent/HK1201750A1/zh unknown
-
2019
- 2019-03-04 JP JP2019038434A patent/JP2019108368A/ja active Pending
-
2021
- 2021-03-24 JP JP2021050188A patent/JP2021102637A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274318A (en) | Cancer treatment with rapamycin target site kinase inhibitors | |
| HK1243919A1 (zh) | 利用tor激酶抑制劑治療癌症 | |
| HK1202247A1 (zh) | 激酶抑制劑治療癌症 | |
| HK1201750A1 (zh) | 使用 激酶抑制劑的癌症治療 | |
| HK1220640A1 (zh) | 用谷氨醯胺酶的雜環抑制劑治療癌症 | |
| HK1201753A1 (zh) | 使用 激酶抑制劑的癌症治療 | |
| ZA201503105B (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| EP2903644A4 (en) | TREATMENT OF CANCER | |
| GB201217892D0 (en) | Treatment of cancer | |
| HK1204956A1 (zh) | 癌症治療 | |
| HK1205500A1 (zh) | 用於癌症治療的激酶抑制劑 | |
| EP2897607A4 (en) | BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| GB201217890D0 (en) | Treatment of cancer | |
| ZA201502294B (en) | Treatment of cancer with tor kinase inhibitors | |
| GB201208296D0 (en) | Treatment of cancer |